Capricor Therapeutics Inc (CAPR) Directors and Executive Officers

Officers & Directors

Executives:
- Linda Marben, Ph.D. - President and Chief Executive Officer
- Anthony Bergmann, CPA - Chief Financial Officer
- AJ Bergmann - Chief Operating Officer
- Benjamin Gold - General Counsel & Corporate Secretary
- John Leone, Ph.D. - Senior Vice President of Regulatory Affairs, Quality and CMC

Directors:
- David McIntyre - Chairman of the Board
- Mark Goldberg, MD - Director
- Roger J. Hajjar, MD - Director
- Giora Feuerstein, Ph.D. - Director
- Craig W

Capricor Therapeutics inc currently has 231 employees.

News about Capricor Therapeutics inc Key Personnel

Capricor Therapeutics Advances Towards a New Dawn in Duchenne Muscular Dystrophy Treatment with Deramiocel

In the ever-evolving landscape of biopharmaceutical innovation, hope often hinges on the breakthroughs of tomorrow. Capricor Therapeutics, a pioneering company in the realm of advanced therapeutic modalities, has announced an exciting development that could significantly impact the lives of individuals suffering from Duchenne Muscular Dystrophy (DMD) cardiomyopathy. The company has initiated a rolling submission for a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for its groundbreaking drug, Deramiocel. This therapeutic advance marks a significant milestone in the quest to address one of the most debilitating manifestations of DMD.DMD is a rare genetic disorder characte...

Capricor Therapeutics' Inclusion in Russell 2000 and Russell 3000 Indexes Puts It on the Map for Revolutionary Rare Disease Therapeutics

Capricor Therapeutics Set to Join Russell 2000 and Russell 3000 Indexes
San Diego-based biotechnology company, Capricor Therapeutics (NASDAQ: CAPR), has announced its inclusion in the prestigious Russell 2000 Index and the broad-market Russell 3000 Index, effective from July 1, 2024. Capricor Therapeutics is focused on developing revolutionary cell and exosome-based therapeutics for the treatment of rare diseases, marking a significant milestone for the company s growth and recognition within the industry.
Capricor Therapeutics successful inclusion in these renowned indexes highlights the company s positive trajectory and potential for future success. The Russell 2000 Index includes 2,000 small...